Lynkuet (Elinzanetant): What This New Hot Flash Pill Does

Lynkuet is the brand name for elinzanetant, a hormone-free prescription pill approved by the FDA on October 24, 2025 to treat moderate-to-severe vasomotor symptoms — the medical term for hot flashes and night sweats — caused by menopause. Made by Bayer, it is taken as a single 120 mg capsule once a day, with or without food.

What makes Lynkuet notable is its mechanism. It is the first and only dual neurokinin-1 (NK-1) and neurokinin-3 (NK-3) receptor antagonist approved for menopause. In plain terms, it blocks two brain signals involved in triggering hot flashes, rather than one. This builds on the newer class of nonhormonal drugs that target the brain's temperature control directly, instead of adding estrogen back into the body.

For decades, the most effective hot flash treatment was hormone therapy (HRT), and it still is a first-line option for many women. But not everyone can take estrogen — for example, those with a history of certain breast cancers, blood clots, or strokes — and some simply prefer to avoid hormones. Lynkuet gives these women a targeted, science-backed alternative. If you want to compare the hormonal path, our guide on [when to start HRT](/blog/when-to-start-hrt-the-timing-hypothesis-explained) explains the timing hypothesis and who benefits most.

Elinzanetant stops hot flashes by calming overactive nerve cells in the brain's temperature-control center, the hypothalamus. During menopause, falling estrogen causes a group of neurons called KNDy neurons to become enlarged and overactive. These neurons use neurokinin B as a signal, and when they fire too much, they trip the body's “too hot” alarm — producing the sudden flush, sweat, and heat of a hot flash even when the room is cool.

Elinzanetant blocks the NK-3 receptor, which quiets those overactive KNDy neurons and resets the temperature threshold. This is the same core pathway targeted by the earlier drug fezolinetant (Veozah). You can read how that one works in our guide to [Veozah (fezolinetant)](/blog/veozah-fezolinetant-nonhormonal-hot-flash-treatment-explained).

What sets elinzanetant apart is that it also blocks the NK-1 receptor, which is involved in sleep, mood, and how the body processes discomfort. Researchers believe this second target is why elinzanetant showed benefits for sleep quality in trials, not just daytime flashes. Because it does not use hormones, it does not carry the estrogen-related risks that make HRT off-limits for some women. It is a precise, brain-targeted approach rather than a whole-body hormonal one.

Lynkuet works well and quickly according to the OASIS clinical trial program, which tested elinzanetant against placebo in postmenopausal women with frequent hot flashes. In OASIS 1 and OASIS 2 (published in JAMA, 2024), women taking elinzanetant saw a large drop in both the frequency and severity of hot flashes compared with placebo, with meaningful improvement starting within the first weeks.

The numbers are striking. By week 12, women on elinzanetant reported roughly a 73% reduction in hot flash frequency and severity — falling from about 6.7 episodes per day to 1.6. Benefits appeared early, often within the first four weeks, and were sustained over time. OASIS 3 followed 627 women for up to 52 weeks and confirmed the drug's longer-term safety profile.

Beyond hot flashes, participants also reported better sleep and improved menopause-related quality of life, which researchers link to the NK-1 blocking action. The overall safety profile was favorable, with the FDA advising monitoring of liver enzymes as a precaution, similar to other drugs in this area. As with any medication, results vary from person to person, but for many women a 70%-plus reduction in flashes is genuinely life-changing. If night sweats are your main problem, our guide to [menopause night sweats](/blog/menopause-night-sweats-causes-and-how-to-stop-them) pairs well with this treatment overview.

Lynkuet is a strong option for women with moderate-to-severe hot flashes who cannot take estrogen or prefer not to. That includes women with a history of hormone-sensitive breast cancer, blood clots, stroke, or certain liver or heart conditions where HRT is not recommended. It is also a good fit for women who tried hormone therapy and did not tolerate it, or who simply want a hormone-free approach.

It may be especially appealing if sleep disruption is a big part of your menopause experience, since the NK-1 targeting appears to help with rest. Many women find that night sweats and fragmented sleep drive daytime fatigue and mood changes, so improving sleep can have ripple effects. If that sounds familiar, our pieces on [menopause fatigue](/blog/menopause-fatigue-why-youre-exhausted-and-what-helps) and [menopause anxiety](/blog/menopause-anxiety-why-it-spikes-and-what-helps) explain those connections.

Lynkuet is not for everyone. It is not used during pregnancy or breastfeeding, and your doctor will likely check liver function before and during treatment. Women who can safely take estrogen and want the broadest symptom relief — including bone and vaginal benefits — may still choose HRT first. The best choice depends on your health history, your symptoms, and your preferences, which is exactly the kind of conversation to have with a menopause-informed clinician.

Compared with older nonhormonal choices, Lynkuet is more targeted and generally more effective for hot flashes, though the right pick depends on your other symptoms. Before this new drug class, doctors often used low-dose SSRIs and SNRIs (antidepressants), the blood pressure drug clonidine, or the nerve medication gabapentin off-label. These can help, but relief is usually more modest and side effects like drowsiness or nausea are common. Our guide to [SSRIs and SNRIs for hot flashes](/blog/ssris-snris-for-hot-flashes-nonhormonal-menopause-guide) covers those in depth.

Within the newer, brain-targeted class, the two options are Veozah (fezolinetant), approved in 2023, and now Lynkuet (elinzanetant). Both are hormone-free and both work on the KNDy-neuron pathway. The key difference is that Lynkuet adds NK-1 blocking, which is linked to its sleep benefits, while Veozah targets NK-3 alone. Both require attention to liver health.

Supplements like black cohosh or magnesium are popular but have far weaker evidence for hot flashes than any prescription option. They may be worth trying for mild symptoms, but women with disruptive, frequent flashes usually need more. The bottom line: if you want a hormone-free medication with strong recent data, Lynkuet is one of the most effective choices now available — discuss it alongside HRT and Veozah with your clinician.